CN105849118B - 大环hcv ns3抑制三肽的合成 - Google Patents

大环hcv ns3抑制三肽的合成 Download PDF

Info

Publication number
CN105849118B
CN105849118B CN201480070017.2A CN201480070017A CN105849118B CN 105849118 B CN105849118 B CN 105849118B CN 201480070017 A CN201480070017 A CN 201480070017A CN 105849118 B CN105849118 B CN 105849118B
Authority
CN
China
Prior art keywords
compound
formula
salt
crystal
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480070017.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105849118A (zh
Inventor
A·卡库拉达
J·常
L·常
D·A·科尔比
K·K·卡尔基
D·卡托
K·A·凯顿
S·康达帕利
C·勒文斯
A·利特克
R·马丁内斯
D·皮乔恩
T·雷诺尔斯
B·罗斯
M·桑吉
A·J·施里尔
P·森
D·西格尔
N·夏皮罗
D·唐
J·G·泰勒
J·特里普
L·于
A·W·瓦特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Gilead Pharmasset LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Gilead Pharmasset LLC filed Critical Gilead Sciences Inc
Priority to CN202310617293.7A priority Critical patent/CN116813596A/zh
Priority to CN202010152008.5A priority patent/CN111320610B/zh
Publication of CN105849118A publication Critical patent/CN105849118A/zh
Application granted granted Critical
Publication of CN105849118B publication Critical patent/CN105849118B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/10—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/12—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton being acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/61—Carboxylic acid nitriles containing cyano groups and nitrogen atoms being part of imino groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
CN201480070017.2A 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成 Active CN105849118B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310617293.7A CN116813596A (zh) 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成
CN202010152008.5A CN111320610B (zh) 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920446P 2013-12-23 2013-12-23
US61/920,446 2013-12-23
PCT/US2014/071319 WO2015100145A1 (en) 2013-12-23 2014-12-18 Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202010152008.5A Division CN111320610B (zh) 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成
CN202310617293.7A Division CN116813596A (zh) 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成

Publications (2)

Publication Number Publication Date
CN105849118A CN105849118A (zh) 2016-08-10
CN105849118B true CN105849118B (zh) 2020-03-31

Family

ID=52278856

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201480070017.2A Active CN105849118B (zh) 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成
CN202310617293.7A Pending CN116813596A (zh) 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成
CN202010152008.5A Active CN111320610B (zh) 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202310617293.7A Pending CN116813596A (zh) 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成
CN202010152008.5A Active CN111320610B (zh) 2013-12-23 2014-12-18 大环hcv ns3抑制三肽的合成

Country Status (20)

Country Link
US (2) US9440991B2 (enExample)
EP (1) EP3087085B1 (enExample)
JP (1) JP6425727B2 (enExample)
KR (1) KR102366697B1 (enExample)
CN (3) CN105849118B (enExample)
AR (1) AR098959A1 (enExample)
AU (1) AU2014370125B2 (enExample)
CA (1) CA2934537C (enExample)
EA (1) EA201691031A1 (enExample)
ES (1) ES2724460T3 (enExample)
IL (1) IL246064A0 (enExample)
MX (1) MX2016008452A (enExample)
NZ (1) NZ720745A (enExample)
PL (1) PL3087085T3 (enExample)
PT (1) PT3087085T (enExample)
SG (1) SG11201604482QA (enExample)
SI (1) SI3087085T1 (enExample)
TR (1) TR201906413T4 (enExample)
TW (3) TWI762003B (enExample)
WO (1) WO2015100145A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3027171T (pt) 2013-07-30 2020-06-18 Gilead Connecticut Inc Formulação de inibidores da syk
MX2016001304A (es) 2013-07-30 2016-04-07 Gilead Connecticut Inc Polimorfo de inhibidores de syk.
AU2014370125B2 (en) 2013-12-23 2017-11-16 Gilead Sciences, Inc. Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9809576B1 (en) 2014-07-18 2017-11-07 Abbvie Inc. Synthetic route to anti-viral agents
US9809534B1 (en) * 2014-07-21 2017-11-07 Abbvie Inc. Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
US10316338B1 (en) 2015-01-30 2019-06-11 Abb Vie Inc. Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid
US10450291B2 (en) 2015-06-29 2019-10-22 Central Glass Company, Limited Method for producing fluorine-containing cyclopropane carboxylic acid compound
JP2020505952A (ja) 2017-02-01 2020-02-27 アッヴィ・インコーポレイテッド （±）−２−（ジフルオロメチル）−１−（アルコキシカルボニル）シクロプロパンカルボン酸及び（±）−２−（ビニル）−１−（アルコキシカルボニル）シクロプロパンカルボン酸の酵素的製造方法
WO2019084740A1 (zh) * 2017-10-31 2019-05-09 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN107739319A (zh) * 2017-10-31 2018-02-27 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN107827748A (zh) * 2017-11-14 2018-03-23 安徽华胜医药科技有限公司 一种乙酸2‑烯丙基环丙酯消旋体的合成方法
KR102519417B1 (ko) 2018-11-28 2023-04-10 삼성디스플레이 주식회사 스트레처블 표시 장치
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
CN116041181A (zh) * 2023-01-04 2023-05-02 广州巨元生化有限公司 一种制备4-卤代-2-甲基-2-丁烯酸烃基酯的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159285A (zh) * 2008-07-22 2011-08-17 默沙东公司 作为hcv ns3蛋白酶抑制剂的大环喹喔啉化合物
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CN104540832A (zh) * 2012-07-03 2015-04-22 吉利德科学公司 丙型肝炎病毒的抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006125446A (ru) * 2003-12-15 2008-01-27 Джапан Тобакко Инк. (Jp) Производные n-замещенного n-сульфониламиноциклопропана и их фармацевтическое применение
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8211891B2 (en) 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2289880A1 (en) * 2009-07-08 2011-03-02 Bayer CropScience AG 2-Pyridinylcyclopropylbenzamide fungicides
SG188618A1 (en) * 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
AR084217A1 (es) * 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
WO2015095430A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Methods and intermediates for the preparation of macrolactams
AU2014370125B2 (en) 2013-12-23 2017-11-16 Gilead Sciences, Inc. Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide
ES2708993T3 (es) * 2013-12-23 2019-04-12 Gilead Sciences Inc Formas cristalinas de un tripéptido macrocíclico inhibidor de NS3 del VHC

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159285A (zh) * 2008-07-22 2011-08-17 默沙东公司 作为hcv ns3蛋白酶抑制剂的大环喹喔啉化合物
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CN104540832A (zh) * 2012-07-03 2015-04-22 吉利德科学公司 丙型肝炎病毒的抑制剂

Also Published As

Publication number Publication date
HK1222401A1 (zh) 2017-06-30
CA2934537A1 (en) 2015-07-02
TW201609711A (zh) 2016-03-16
TWI762003B (zh) 2022-04-21
CN116813596A (zh) 2023-09-29
KR102366697B1 (ko) 2022-02-25
AU2014370125A1 (en) 2016-06-23
JP6425727B2 (ja) 2018-11-21
US20170210756A1 (en) 2017-07-27
AU2014370125B2 (en) 2017-11-16
SI3087085T1 (sl) 2019-05-31
TWI671292B (zh) 2019-09-11
TWI710547B (zh) 2020-11-21
CA2934537C (en) 2022-08-16
US9440991B2 (en) 2016-09-13
EP3087085A1 (en) 2016-11-02
IL246064A0 (en) 2016-07-31
MX2016008452A (es) 2016-10-14
KR20160101934A (ko) 2016-08-26
CN111320610A (zh) 2020-06-23
US10030033B2 (en) 2018-07-24
JP2017509585A (ja) 2017-04-06
SG11201604482QA (en) 2016-07-28
NZ720745A (en) 2018-02-23
CN111320610B (zh) 2023-06-06
US20150175626A1 (en) 2015-06-25
EP3087085B1 (en) 2019-02-20
TR201906413T4 (tr) 2019-05-21
WO2015100145A1 (en) 2015-07-02
PL3087085T3 (pl) 2019-07-31
ES2724460T3 (es) 2019-09-11
TW202106661A (zh) 2021-02-16
TW201938527A (zh) 2019-10-01
EA201691031A1 (ru) 2017-01-30
AR098959A1 (es) 2016-06-22
CN105849118A (zh) 2016-08-10
PT3087085T (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
CN105849118B (zh) 大环hcv ns3抑制三肽的合成
JP6954959B2 (ja) 抗ウイルス化合物を調製するためのプロセス
RU2636943C2 (ru) Получение антивирусного соединения
HK1225388A1 (zh) 通过环化2-(氨基乙氧基)苯甲酸衍生物制备3，4-二氢-1，4-苯并氧氮杂环庚三烯-5(2h)-酮衍生物
HK40022676A (en) Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
HK40022676B (en) Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
HK1222401B (zh) 大环hcv ns3抑制三肽的合成
HK1230216A1 (en) Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
HK1230216B (en) Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
HK1236198B (en) Processes for preparing antiviral compounds
HK1236198A1 (en) Processes for preparing antiviral compounds
HK1234751A1 (en) Processes for preparing antiviral compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1222401

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190418

Address after: American California

Applicant after: Pharmasset Inc.

Address before: American California

Applicant before: Gilead Sciences Inc.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20211124

Address after: California, USA

Patentee after: GILEAD SCIENCES, Inc.

Address before: California, USA

Patentee before: GILEAD PHARMASSET LLC